Cost-effectiveness analysis of treatment with epoietin-α for patients with anaemia due to renal failure: The case of Sweden

References

• Locatelli F, Pisoni RL, Akizawa T, Cruz JM, DeOreo PB, Lamiere NH, et al. Anemia management for hemodialysis patients: Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines and Dialysis Outcomes and Practice Patterns Study (DOPPS) findings. Am J Kidney Dis 2004; 44: S27–33
   PubMed Web of Science ®Google Scholar
• Pisoni RL, Bragg-Gresham JL, Young EW, Akizawa T, Asano Y, Locatelli F, et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004; 44: 94–111
   PubMed Web of Science ®Google Scholar
• Riktlinjer för omhändertagande av patienter med njursvikt (Clinical practice guidelines for renal failure patients in Sweden). Svensk Njurmedicinsk Förening (Swedish Renal Association). Göteborg; 2000.
   Google Scholar
• Remák E, Hutton J, Jones M, Zagari M. Changes in cost-effectiveness over time. The case of Epoetin Alfa for renal replacement therapy patients in the UK. Eur J Health Econ 2003; 4: 115–21
   PubMedGoogle Scholar
• Dialys i Sverige 2004 (Dialysis in Sweden 2004). SDDB, Svensk Njurmedicinsk Förening (Swedish Dialysis Database, Swedish Renal Association). Göteborg; 2005.
   Google Scholar
• Nationella tvärsnittsundersökningen Hösten 2002 (National cross sectional survey – Fall 2002). SDDB, Svensk Njurmedicinsk Förening (Swedish Dialysis Database, Swedish Renal Association). Göteborg; 2003.
   Google Scholar
• www.medscinet.com/sddb.
   Google Scholar
• Aktiv uremivård i Sverige 1991–2004 (Active treatment of uremia in Sweden 1991–2004). SRAU (Swedish Registry for Active Treatment of Uremia). Göteborg; 2005.
   Google Scholar
• The Swedish Association of the Pharmaceutical Industry/FASS. Pharmaceutical Specialities in Sweden. Stockholm: Linfo; 2007. Available from: www.fass.se.
   Google Scholar
• Wilson J, Yao GL, Raftery J, Bohlius J, Brunskill S, Sandercock J, et al. A systematic review and economic evaluation of epoetin alfa, epoetin beta and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess 2007; 11: 1–220
   PubMed Web of Science ®Google Scholar
• Southern Regional Health Care Board. Prices and reimbursements for the Southern Health Care Region, 2007. Southern Regional Health Care Board. Lund; 2006. Available from: www.srvn.org.
   Google Scholar
• Furuland H, Linde T, Ahlmén J, Christensson A, Strömbom U, Danielson BG. A randomized controlled trial of haemoglobin normalization with epoietin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant 2003; 18: 353–61
   PubMed Web of Science ®Google Scholar
• Crémieux PY, Barrett B, Anderson K, Slavin MB. Cost of outpatient blood transfusion in cancer patients. J Clin Oncol 2000; 18: 2755–61
   PubMed Web of Science ®Google Scholar
• Sonnenberg FA, Gregory P, Yomtovian GR, Russel LB, Tierney W, Kosmin M, et al. The cost-effectiveness of autologous transfusion revisited: implications of an increased risk of bacterial infection with allogeneic transfusion. Transfusion 1999; 39: 808–17
   PubMed Web of Science ®Google Scholar
• Shanwell A. Blodtransfusion aldrig helt biverkningsfri—Filtrerade erytrocytkoncentrat bör användas (Blood transfusion is never completely without side-effects. Filtrated erythrocyte concentrates should be used). Läkartidningen 2000; 97: 1782–7
   PubMedGoogle Scholar
• Berseus O, Norda R. Kartläggning av Sveriges blodförsörjning. Socialstyrelsen, Stockholm 2002; 2004
   Google Scholar
• Coyle D, Lee KM, Fergusson D, Laupacis A. Cost effectiveness of epoetin-alpha to augment preoperative autologous blood donation in elective cardiac surgery. Pharmacoeconomics 2000; 18: 161–71
   PubMed Web of Science ®Google Scholar
• Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Br Med J 1990;300:573–8.
   PubMed Web of Science ®Google Scholar
• Stevens MR, Summerfield GP, Hall AA, Bech CA, Harding A, Cove-Smith JR, et al. Cost benefits of low dose subcutaneous erythropoietin in patients with anaemia of end stage renal disease. Br Med J 1992; 304: 474–7
   PubMed Web of Science ®Google Scholar
• Moreno F, Aracil FJ, Perez R, Valderrabano F. Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia with erythropoietin. Am J Kidney Dis 1996; 27: 548–56
   PubMed Web of Science ®Google Scholar
• Muirhead N, Laupacis A, Wong C. Erythropoietin for anaemia in haemodialysis patients: results of a maintenance study (the Canadian Erythropoietin Study Group). Nephrol Dial Transplant 1992; 7: 811–6
   PubMed Web of Science ®Google Scholar
• Harris DCH, Lawrence S, Chapman JR, Roger SD, Stewart JH. Low dose erythropoietin in maintenance haemodialysis: improvement in quality of life and reduction in true cost of haemodialysis. Aust N Z J Med 1991; 21: 693–700
   PubMedGoogle Scholar
• Leese B, Hutton J, Maynard AK. The costs and benefits of the use of erythropoietin in the treatment of anaemia arising from chronic renal failure: a European study. Centre for Health Economics, University of York, YorkUK 1990
   Google Scholar
• Tonelli M, Winkelmayer WC, Jindal KK, Owen WF, Manns BJ. The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients. Kidney Int 2003; 64: 295–304
   PubMed Web of Science ®Google Scholar
• Perlman RL, Finkelstein FO, Liu L, Roys E, Kiser M, Eisele G, et al. Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the Renal Research Institute-CKD study. Am J Kidney Dis 2005; 45: 658–66
   PubMed Web of Science ®Google Scholar
• Lefebvre P, Vekeman F, Sarokhan B, Enny C, Provenzano R, Cremieux PY. Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa. Curr Med Res Opin 2006; 22: 1929–37
   PubMed Web of Science ®Google Scholar
• Merkus MP, Jager KJ, Dekker FW, Boeschoten EW, Stevens P, Krediet RT. Quality of life in patients on chronic dialysis: self-assessment 3 months after the start of treatment. Am J Kidney Dis 1997; 29: 584–92
   PubMed Web of Science ®Google Scholar
• Manns B, Johnson JA, Taub K, Mortis G, Ghali WA, et al. Quality of life in patients treated with hemodialysis or peritoneal dialysis: what are the important determinants?. Clin Nephrol 2003; 60: 341–51
   PubMed Web of Science ®Google Scholar
• Churchill WH, Torrance GW, Taylor DW, Barnes CC, Ludwin D. Measurement of quality of life in end-stage renal disease: the time-trade-off approach. Clin Invest Med 1987; 1: 14–20
   Google Scholar
• De Wit GA, Ramsteijn PG, de Charro FT. Economic evaluation of end stage renal disease treatment. Health Policy 1998; 44: 215–32
   PubMed Web of Science ®Google Scholar
• Merkus MP, Jager KJ, Dekker FW, De Haan RJ, Boeschoten EW, Krediet RT. Quality of life over time in dialysis: the Netherlands Cooperative Study on the Adequacy of Dialysis. Kidney Int 1999; 56: 720–8
   PubMed Web of Science ®Google Scholar
• The Swedish Pharmaceutical Benefits Board. General guidelines regarding economic evaluations. SolnaSweden: The Swedish Pharmaceutical Benefits Board; 2003 ( in Swedish).
   Google Scholar
• Rayner HC, Pisoni RL, Bommer J, Canaud B, Hecking E, Locatelli F, et al. Mortality and hospitalization in haemodialysis patients in five European countries: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004; 19: 108–20
   PubMed Web of Science ®Google Scholar
• Persson U, Hjelmgren J. Health services need knowledge of how the public values health. Läkartidningen 2003;100:3436–7 (in Swedish).
   PubMedGoogle Scholar
• Ansell D, Feest T, Byrne C, Ahmad A. UK Renal Registry Report 2003: The sixth annual report. Bristol, UK: The Renal Association, UK Renal Registry; 2003. Available from: http://www.renalreg.com/Report%202003/Cover3_Frames.htm.
   Google Scholar
• Swedish National Board of Health and Welfare. Patient data register of the Swedish National Board of Health and Welfare. Swedish National Board of Health and Welfare, Stockholm; 2007.
   Google Scholar